Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
10.15(c) 10.39(c) 12.26(c) 12.22(c) 12.42(c) Last
9 927 550 11 057 299 21 178 705 23 173 490 20 151 126 Volume
-2.22% +2.36% +18.00% -0.33% +1.64% Change
More quotes
Financials (USD)
Sales 2020 4,06 M - -
Net income 2020 -181 M - -
Net Debt 2020 - - -
P/E ratio 2020 -10,4x
Yield 2020 -
Sales 2021 143 M - -
Net income 2021 -156 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,7x
Yield 2021 -
Capitalization 2 070 M 2 070 M -
Capi. / Sales 2020 510x
Capi. / Sales 2021 14,5x
Nbr of Employees 190
Free-Float 97,8%
More Financials
Company
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target... 
More about the company
Notations Surperformance© of Inovio Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about INOVIO PHARMACEUTICALS, INC.
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/23INOVIO PHARMACEUTICALS : Announces Dosing of First Subject in Phase 1/2 Clinical..
PR
11/20INOVIO PHARMACEUTICALS : Presents Clinical Results of its DNA Medicines INO-5401..
PR
11/18PFIZER, MODERNA COVID-19 VACCINES MA : U.S. official
RE
11/16INOVIO PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
11/16INOVIO PHARMACEUTICALS : to begin mid-stage study of COVID-19 vaccine candidate
RE
11/16INOVIO PHARMACEUTICALS : to begin mid-stage study of COVID-19 vaccine candidate
RE
11/16INOVIO PHARMACEUTICALS : Announces Initiation of Phase 2 Segment of its Phase 2/..
PR
11/10Arcturus expects its COVID-19 vaccine to be ready by Q1 2021
RE
11/09GRAPHIC : Tracking the vaccine race
RE
11/09INOVIO : 3Q Earnings Snapshot
AQ
11/09INOVIO PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results
PR
11/09INOVIO PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
11/02CEPI to fund development of COVID-19 vaccine candidate by China's Clover
RE
10/26INOVIO PHARMACEUTICALS : to Report Third Quarter 2020 Financial Results on Novem..
PR
More news
News in other languages on INOVIO PHARMACEUTICALS, INC.
08/11Wall Street, lestée par la tech, finit dans le rouge
07/01BioNTech treibt Corona-Impfstoffprojekt nach positiven Daten voran
06/23WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
06/04WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
06/03Coronavirus-Les USA retiennent 5 candidats vaccins, pas Sanofi-NYT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Stock Trading Strategies
INOVIO PHARMACEUTICALS, INC. - 05/22
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,71 $
Last Close Price 12,22 $
Spread / Highest target 105%
Spread / Average Target 12,2%
Spread / Lowest Target -34,5%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.270.30%2 070
MODERNA, INC.680.88%60 441
LONZA GROUP AG61.27%46 692
CELLTRION, INC.82.04%41 055
IQVIA HOLDINGS INC.9.37%32 400
SEAGEN INC.49.05%30 708